Nature Communications (Aug 2021)
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
- Xiaohong Tan,
- Lu Tong,
- Lin Li,
- Jinjin Xu,
- Shaofang Xie,
- Lei Ji,
- Junjiang Fu,
- Qingwu Liu,
- Shihui Shen,
- Yun Liu,
- Yanhui Xiao,
- Feiran Gao,
- Robb E. Moses,
- Nabeel Bardeesy,
- Yanxiao Wang,
- Jishuai Zhang,
- Longying Tang,
- Lei Li,
- Kwok-kin Wong,
- Dianwen Song,
- Xiao Yang,
- Jian Liu,
- Xiaotao Li
Affiliations
- Xiaohong Tan
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics
- Lu Tong
- Institute of Biomedical Engineering, School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology
- Lin Li
- Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University
- Jinjin Xu
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Shaofang Xie
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Lei Ji
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Junjiang Fu
- Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University
- Qingwu Liu
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Shihui Shen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Yun Liu
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Yanhui Xiao
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Feiran Gao
- Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, International Campus, Zhejiang University
- Robb E. Moses
- Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza
- Nabeel Bardeesy
- Cancer Center, Massachusetts General Hospital
- Yanxiao Wang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics
- Jishuai Zhang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics
- Longying Tang
- Shanghai Changning Maternity and Infant Health Hospital.
- Lei Li
- Institute of Biomedical Engineering, School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology
- Kwok-kin Wong
- Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center
- Dianwen Song
- Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine
- Xiao Yang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics
- Jian Liu
- Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, International Campus, Zhejiang University
- Xiaotao Li
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- DOI
- https://doi.org/10.1038/s41467-021-24898-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
The underlying mechanisms by which Smad4 loss-of-function accelerates lung cancer metastasis is unclear. Here, the authors show PAK3 as a downstream effector of Smad4 promoting metastatic signalling and suggest Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
